Oruka Therapeutics (NASDAQ:ORKA) Receives Outperform Rating from Wedbush

Key Points

• Wedbush reaffirmed its Outperform rating on Oruka Therapeutics with a $165 price target, implying approximately 93% upside from the reported $85.49 share price. The analyst consensus remains “Moderate Buy,” with an average target of $128.91.
• Oruka shares fell 4.9% to $85.49 during Thursday’s trading session. The company reported a quarterly loss of $0.55 per share, missing the $0.51 consensus estimate.
• Clinical updates for ORKA-001 were positive: Phase 2a psoriasis data showed PASI 100 and PASI 90 responses continuing to deepen through Week 28 without additional dosing, although safety disclosures may have weighed on investor sentiment.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at Wedbush in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $165.00 target price on the stock. Wedbush's price objective would indicate a potential upside of 93.01% from the company's current price.

Other equities analysts have also issued reports about the company. Guggenheim reissued a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Weiss Ratings raised Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. HC Wainwright reissued a "buy" rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Finally, BTIG Research reissued a "buy" rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $128.91.

Oruka Therapeutics Stock Down 4.9%

Shares of NASDAQ:ORKA traded down $4.44 during trading on Thursday, hitting $85.49. 1,294,347 shares of the company traded hands, compared to its average volume of 1,104,068. The stock has a market capitalization of $5.66 billion, a price-to-earnings ratio of -42.11 and a beta of -0.34. The business's fifty day moving average is $96.79 and its 200-day moving average is $75.32. Oruka Therapeutics has a one year low of $14.89 and a one year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, analysts forecast that Oruka Therapeutics will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the transaction, the insider directly owned 31,771 shares of the company's stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 533 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $95.75, for a total value of $51,034.75. Following the transaction, the senior vice president directly owned 14,219 shares of the company's stock, valued at approximately $1,361,469.25. The trade was a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,950 shares of company stock worth $11,528,806 over the last ninety days. Company insiders own 23.49% of the company's stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. Nykredit A S bought a new position in Oruka Therapeutics during the 2nd quarter valued at $29,000. Caitong International Asset Management Co. Ltd bought a new position in Oruka Therapeutics during the 4th quarter valued at $67,000. Orion Capital Management LLC bought a new position in Oruka Therapeutics during the 2nd quarter valued at $91,000. Royal Bank of Canada boosted its stake in Oruka Therapeutics by 178.5% during the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company's stock valued at $155,000 after purchasing an additional 2,033 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in Oruka Therapeutics by 119.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company's stock valued at $156,000 after purchasing an additional 1,736 shares in the last quarter. 56.44% of the stock is owned by institutional investors.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 delivered strong and durable psoriasis results. In the Phase 2a EVERLAST-A trial, PASI 100 responses increased to 71.4% and PASI 90 responses reached 87.3% by Week 28, despite no additional dosing after Week 4. Patients who crossed over from placebo achieved similar response rates, while the company reported a favorable safety and tolerability profile. Oruka expects additional 16-week EVERLAST-B data in the fourth quarter of 2026 and 52-week EVERLAST-A data in December. Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001
• Positive Sentiment: Analysts remain bullish. Wedbush reaffirmed its outperform rating with a $165 price target, while HC Wainwright reiterated its buy rating and set a $120 target. The recommendations suggest analysts see substantial upside if Oruka’s clinical program continues to validate its potential. Analyst ratings for Oruka Therapeutics
• Neutral Sentiment: ORKA-002 is advancing in hidradenitis suppurativa. Oruka provided an update on its ongoing randomized, double-blind, placebo-controlled clinical study, but the report did not provide major new efficacy or safety results. ORKA-002 Trial Progress
• Neutral Sentiment: Reported short-interest data showed zero shares short as of September 24, implying a zero-day short-interest ratio. The figure may have limited relevance for trading sentiment and appears inconsistent with the description of a large increase in short interest.
• Negative Sentiment: Safety disclosures may have overshadowed the positive efficacy data. Commentary noted that investors focused on safety information accompanying the Week 28 update, helping explain why the stock declined even as psoriasis responses deepened. ORKA Stock Down Despite Positive Week 28 Data

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company's research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka's initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.